Mark Dawson, an epigenetics specialist, has joined the scientific advisory board of Storm Therapeutics Ltd which is investigating small molecule therapies modulating RNA epigenetics. Professor Dawson is a clinician-scientist at the Centre of Cancer Research at the University of Melbourne, Australia.
Also joining the board is Paul Leeson, a medicinal chemist, who has worked in drug discovery and development at multiple large pharma companies including AstraZeneca Plc and GlaxoSmithKline Plc. Storm was founded in 2015 and has raised £16 million in Series A financing.
Storm Therapeutics announced the appointments on 11 December 2017.
Copyright 2018 Evernow Publishing Ltd